Gene Therapy Prolongs Survival and Restores Function in Murine and Canine Models of Myotubular Myopathy
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Intravenous injection of an adeno-associated viral vector expressing the myotubularin ( MTM1 ) gene improves survival and rescues skeletal muscle function in mice and dogs affected by myotubular myopathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the Mtm1-deficient mice, rAAV8.desmin.Mtm1, at 3 × 1013 vg/kg corrected muscle pathology and prolonged survival throughout the 6-month study.”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [37]
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Self-citationImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655
Laporte, J., Hu, L. J., Kretz, C., Mandel, J.-L., Kioschis, P., Coy, J. F., Klauck, S. M., Poustka, A., & Dahl, N. (1996) · Nature Genetics · doi:10.1038/ng0696-175 · Cited by 639 · cited 1×
“XLMTM results from loss-of-function mutations in the myotubularin 1 gene (MTM1) (10), which encodes the founder member of a family of 3-phosphoinositide phosphatases acting on the second messengers phosphatidylinositol 3-monophosphate [PI(3)P] and phosphatidylinositol 3,5-bisphosphate [PI(3,5)P2] (11, 12).”
BackgroundSystemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395 · cited 1×
“XLMTM results from loss-of-function mutations in the myotubularin 1 gene (MTM1) (10), which encodes the founder member of a family of 3-phosphoinositide phosphatases acting on the second messengers phosphatidylinositol 3-monophosphate [PI(3)P] and phosphatidylinositol 3,5-bisphosphate [PI(3,5)P2] (11, 12).”
BackgroundCentronuclear (myotubular) myopathy
Jungbluth, H., Wallgren-Pettersson, C., & Laporte, J. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-26 · Cited by 321
Smith, R. H., Levy, J. R., & Kotin, R. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.128 · Cited by 261 · cited 1×
“The recombinant adeno-associated virus vector AAV2/8-pDesminMTM1 containing a canine myotubularin cDNA regulated by the desmin promoter (designated AAV8-cMTM1) was produced in a baculovirus/Sf9 system (41).”
MethodCentronuclear myopathies: A widening concept
Romero, N. B. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.01.014 · Cited by 260
Mendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248
Myotubularin phosphatases: policing 3-phosphoinositides
Robinson, F. L., & Dixon, J. E. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.06.001 · Cited by 242
Dowling, J. J., Vreede, A. P., Low, S. E., Gibbs, E. M., Kuwada, J. Y., Bonnemann, C. G., & Feldman, E. L. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000372 · Cited by 236
Buj-Bello, A., Laugel, V., Messaddeq, N., Zahreddine, H., Laporte, J., Pellissier, J.-F., & Mandel, J.-L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212498399 · Cited by 230 · cited 5×
“The constitutiveKOof themyotubularin gene (KO-Mtm1, also named BS53d4-129pas) was described previously (13, 18).”
BackgroundMethodInfluentialSelf-citationBuchlis, G., Podsakoff, G. M., Radu, A., Hawk, S. M., Flake, A. W., Mingozzi, F., & High, K. A. (2012) · Blood · doi:10.1182/blood-2011-09-382317 · Cited by 221
Greelish, J. P., Su, L. T., Lankford, E. B., Burkman, J. M., Chen, H., Konig, S. K., Mercier, I. M., Desjardins, P. R., Mitchell, M. A., Zheng, X. G., et al. (1999) · Nature Medicine · doi:10.1038/7439 · Cited by 212
Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206
Self-citationAl-Qusairi, L., Weiss, N., Toussaint, A., Berbey, C., Messaddeq, N., Kretz, C., Sanoudou, D., Beggs, A. H., Allard, B., Mandel, J.-L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900705106 · Cited by 197
Self-citationMuscle Function Recovery in Golden Retriever Muscular Dystrophy After AAV1-U7 Exon Skipping
Vulin, A., Barthélémy, I., Goyenvalle, A., Thibaud, J. L., Beley, C., Griffith, G., Benchaouir, R., Hir, M. L., Unterfinger, Y., Lorain, S., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.181 · Cited by 161
Buj-Bello, A., Fougerousse, F., Schwab, Y., Messaddeq, N., Spehner, D., Pierson, C. R., Durand, M., Kretz, C., Danos, O., Douar, A.-M., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn112 · Cited by 132 · cited 4×
“Pseudotyped recombinant AAV2/8 viral preparations were generated by packaging AAV2-inverted terminal repeat recombinant genomes into AAV8 capsids using a tritransfection protocol as previously described (17).”
BackgroundMethodInfluentialSelf-citationTherapeutic approaches to muscular dystrophy
Goyenvalle, A., Seto, J. T., Davies, K. E., & Chamberlain, J. S. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr105 · Cited by 130 · cited 1×
“Preclinical and clinical studies proved that AAV-mediated delivery can lead to transgene expression at therapeutic or subtherapeutic levels in entiremuscles and can correct the disease phenotype in animal models of muscular dystrophy [reviewed in (25)].”
BackgroundCharacterization of the Myotubularin Dual Specificity Phosphatase Gene Family from Yeast to Human
Laporte, J., Blondeau, F., Buj-Bello, A., Tentler, D., Kretz, C., Dahl, N., & Mandel, J.-L. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.11.1703 · Cited by 121 · cited 1×
“XLMTM results from loss-of-function mutations in the myotubularin 1 gene (MTM1) (10), which encodes the founder member of a family of 3-phosphoinositide phosphatases acting on the second messengers phosphatidylinositol 3-monophosphate [PI(3)P] and phosphatidylinositol 3,5-bisphosphate [PI(3,5)P2] (11, 12).”
BackgroundSelf-citationGregorevic, P., Blankinship, M. J., Allen, J. M., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.28 · Cited by 120
MTM1 mutation associated with X-linked myotubular myopathy in Labrador Retrievers
Beggs, A. H., Böhm, J., Snead, E., Kozlowski, M., Maurer, M., Minor, K., Childers, M. K., Taylor, S. M., Hitte, C., Mickelson, J. R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003677107 · Cited by 119 · cited 5×
“The clinical picture closely resembles that of patients with comparably severe mutations, and survival does not normally exceed 4 months (15).”
BackgroundInfluentialSelf-citationArruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P., Chen, Y., Franck, H. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 117
Toromanoff, A., Chérel, Y., Guilbaud, M., Penaud-Budloo, M., Snyder, R. O., Haskins, M. E., Deschamps, J.-Y., Guigand, L., Podevin, G., Arruda, V. R., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.87 · Cited by 99
Self-citationHerson, S., Hentati, F., Rigolet, A., Behin, A., Romero, N. B., Leturcq, F., Laforêt, P., Maisonobe, T., Amouri, R., Haddad, H., et al. (2012) · Brain · doi:10.1093/brain/awr342 · Cited by 91
Self-citationLawlor, M. W., Armstrong, D., Viola, M. G., Widrick, J. J., Meng, H., Grange, R. W., Childers, M. K., Hsu, C. P., O'Callaghan, M., Pierson, C. R., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt003 · Cited by 87
Self-citationAAV Genome Loss From Dystrophic Mouse Muscles During AAV-U7 snRNA-mediated Exon-skipping Therapy
Le Hir, M., Goyenvalle, A., Peccate, C., Précigout, G., Davies, K. E., Voit, T., Garcia, L., & Lorain, S. (2013) · Molecular Therapy · doi:10.1038/mt.2013.121 · Cited by 80 · cited 1×
“In contrast to previous observations in animalmodels ofDMD(24, 38), our data demonstrate relatively long-term expression of AAV-derived myotubularin in muscles of XLMTM mice and dogs treated with a single dose of recombinant vector.”
ResultSu, L. T., Gopal, K., Wang, Z., Yin, X., Nelson, A., Kozyak, B. W., Burkman, J. M., Mitchell, M. A., Low, D. W., Bridges, C. R., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.534008 · Cited by 79
Pierson, C. R., Dulin-Smith, A. N., Durban, A. N., Marshall, M. L., Marshall, J. T., Snyder, A. D., Naiyer, N., Gladman, J. T., Chandler, D. S., Lawlor, M. W., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr512 · Cited by 79
Self-citationWang, Z., Storb, R., Halbert, C. L., Banks, G. B., Butts, T. M., Finn, E. E., Allen, J. M., Miller, A. D., Chamberlain, J. S., & Tapscott, S. J. (2012) · Molecular Therapy · doi:10.1038/mt.2012.111 · Cited by 78
A noninvasive procedure to detect muscle weakness in the mdx mouse
Carlson, C. G., & Makiejus, R. V. (1990) · Muscle & Nerve · doi:10.1002/mus.880130603 · Cited by 74
Kornegay, J. N., Bogan, D. J., Bogan, J. R., Childers, M. K., Cundiff, D. D., Petroski, G. F., & Schueler, R. O. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00118-5 · Cited by 71 · cited 1×
“Hindlimb contraction in dogs Contractile properties in canine muscles in vivo were assessed as previously described (19, 20).”
MethodSelf-citationFan, Z., Kocis, K., Valley, R., Howard, J. F., Chopra, M., An, H., Lin, W., Muenzer, J., & Powers, W. (2012) · Molecular Therapy · doi:10.1038/mt.2011.137 · Cited by 55 · cited 1×
“Science by several forms of muscular dystrophy (31).”
BackgroundSkogstrand, K. (2011) · Methods · doi:10.1016/j.ymeth.2011.09.025 · Cited by 53
Gene Therapy Approaches for Lysosomal Storage Disease: Next-Generation Treatment
Byrne, B. J., Falk, D. J., Clément, N., & Mah, C. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.140 · Cited by 48
Malekzadeh, A., de Groot, V., Beckerman, H., van Oosten, B. W., Blankenstein, M. A., & Teunissen, C. E. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.017 · Cited by 46
Muscle function in A canine model of X‐linked myotubular myopathy
Grange, R. W., Doering, J., Mitchell, E. L., Holder, M., Guan, X., Goddard, M. A., Tegeler, C. J., Beggs, A. H., & Childers, M. K. (2012) · Muscle & Nerve · doi:10.1002/mus.23463 · Cited by 27
Self-citationIn Vivo Canine Muscle Function Assay
Childers, M. K., Grange, R. W., & Kornegay, J. N. (2011) · Journal of Visualized Experiments · doi:10.3791/2623 · Cited by 25 · cited 1×
“Hindlimb contraction in dogs Contractile properties in canine muscles in vivo were assessed as previously described (19, 20).”
MethodSelf-citationJoubert, R., Vignaud, A., Le, M., Moal, C., Messaddeq, N., & Buj-Bello, A. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt038 · Cited by 24
Self-citationLi, Z., Colucci‐Guyon, E., Babinet, C., & Paulin, D. (1993) · Neuromuscular Disorders · doi:10.1016/0960-8966(93)90089-3 · Cited by 17
Establishing Clinical End Points of Respiratory Function in Large Animals for Clinical Translation
Goddard, M. A., Mitchell, E. L., Smith, B. K., & Childers, M. K. (2011) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2011.11.017 · Cited by 15
Self-citationIn Vivo Canine Muscle Function Assay
Childers, M. K., Kornegay, J. N., & Grange, R. W. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/2vr1-rx16 · Cited by 10
Self-citationGene Transfer to Muscle from the Isolated Regional Circulation
Petrov, M., Malik, A. S., Mead, A., Bridges, C. R., & Stedman, H. H. (2010) · Methods in molecular biology · doi:10.1007/978-1-61737-982-6_18 · Cited by 8
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Together, these preclinical studies showed the feasibility, safety, and efficacy of gene therapy with AAV8 for long-term correction of XLMTM.(37,38)”
BackgroundTabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.028 · Cited by 506
“Our therapeutic results are all the more notable given that they were achieved after injecting 10–250 times lower doses of therapeutic vector than those used in previously published preclinical studies based on the same gene therapy approaches (Childers et al., 2014; Elverman et al., 2017; Hakim et al., 2017; Mack et…”
Self-citationCongenital myopathies: disorders of excitation–contraction coupling and muscle contraction
Jungbluth, H., Treves, S., Zorzato, F., Sarkozy, A., Ochala, J., Sewry, C., Phadke, R., Gautel, M., & Muntoni, F. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.191 · Cited by 280
Treating pediatric neuromuscular disorders: The future is now
Dowling, J. J., Gonorazky, H. D., Cohn, R. D., & Campbell, C. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38418 · Cited by 165
Shieh, P. B., Kuntz, N. L., Dowling, J. J., Müller‐Felber, W., Bönnemann, C. G., Seferian, A., Servais, L., Smith, B. K., Muntoni, F., Blaschek, A., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00313-7 · Cited by 163
Self-citation
Metadata
- Authors
- Childers, M. K., Joubert, R., Poulard, K., Moal, C., Grange, R. W., Doering, J. A., Lawlor, M. W., Rider, B. E., Jamet, T., Danièle, N., Martin, S., Rivière, C., Soker, T., Hammer, C., Van Wittenberghe, L., Lockard, M., Guan, X., Goddard, M., Mitchell, E., Barber, J., Williams, J. K., Mack, D. L., Furth, M. E., Vignaud, A., Masurier, C., Mavilio, F., Moullier, P., Beggs, A. H., & Buj-Bello, A.
- Affiliations
- University of Washington (US)
- Genethon (France) (FR)
- Virginia Tech (US)
- Children's Hospital of Wisconsin (US)
- Boston Children's Hospital (US)
- Généthon, 1 bis rue de l’Internationale, 91002 Evry, France.
- Wake Forest University (US)
- Wake Forest Baptist Comprehensive Cancer Center (US)
- Inserm (FR)
- Corresponding author
- Childers, Martin K.
- Beggs, Alan H.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2014-01-22
- Volume
- 6
- Issue
- 220
- Pages
- 220ra10-220ra10
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC4105197
- OpenAlex
- W2118159264
- Cited by
- 173
- References
- 48
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 12 · 2023: 14 · 2022: 11 · 2021: 12 · 2020: 14 · 2019: 18 · 2018: 20 · 2017: 14 · 2016: 11 · 2015: 20 · 2014: 15
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Funders
- National Heart, Lung, and Blood Institute (R01HL115001)
- National Institute of Neurological Disorders and Stroke (P50NS040828)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR064503, R01AR044345, K08AR059750)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD018655)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- myotubular myopathy, X-linked myotubular myopathy, MTM1, myotubularin, gene therapy, AAV8 vector, adeno-associated virus, knockout mice, canine model, muscle function, survival, respiratory dysfunction, muscle weakness, loss-of-function mutations
- MeSH terms
- Dependovirus, Animals, Diaphragm, Disease Models, Animal, Dogs, Genetic Vectors, Genotype, Humans, Male, Muscle Contraction, Mutation, Genetic Therapy, Mice, Knockout, Muscle Weakness, Myopathies, Structural, Congenital, Mice, Protein Tyrosine Phosphatases, Non-Receptor, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.